Main distributor to Brazil and Latin America for analytical reference substances  |  Welcome! Olá! Hola! Español  |  +1.919.484.7555
You are here: Home /COVID-19, Vaccine /Gritstone, NIAID enter clinical trial agreement for next-gen Covid-19 vaccine

Gritstone, NIAID enter clinical trial agreement for next-gen Covid-19 vaccine

by JMC on January 21, 2021

Gritstone has entered into a clinical trial agreement with the US National Institutes of Health (NIH) unit National Institute of Allergy and Infectious Diseases (NIAID) to advance its Covid-19 programme, CORAL, for developing a second-generation vaccine.

Gritstone has entered into a clinical trial agreement with the US National Institutes of Health (NIH) unit the National Institute of Allergy and Infectious Diseases (NIAID) to advance its Covid-19 programme, CORAL, for developing a second-generation vaccine.

Gritstone noted that the vaccine can potentially provide prolonged protection, as well as potency against spike mutants of the virus.

A Phase I clinical trial, set to take place through the NIAID-supported Infectious Diseases Clinical Research Consortium (IDCRC), is in development.

A grant from the Bill & Melinda Gates Foundation will back the preclinical analysis of the vaccine.

Gritstone co-founder, president and CEO Andrew Allen said: “Since inception, Gritstone has developed two core assets – cutting-edge T cell epitope identification and potent vaccines shown to activate a strong and broad immune response in humans – and both of these have been deployed in our quest for a second-generation SARS-CoV-2 vaccine.

“We are excited to be working with the experienced teams at NIAID and the IDCRC as well as the experts at the Gates Foundation and LJI [La Jolla Institute for Immunology] who have helped us design and pre-clinically test our novel vaccine concepts.”

The company can access validated SARS-CoV-2 epitopes through a license agreement with the LJI.

Using the epitopes identified by LJI and its EDGE and vaccine platform technologies, the company is developing a vaccine with spike and additional viral epitopes that offer good targets for T-cell immunity.

Source: https://www.pharmaceutical-technology.com/news/gritstone-niaid-enter-agreement/

Previous post:

Next post: